Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-01

GeneDx Holdings (WGS)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$13,547,219
Katherine Stueland total, FY2025
90th
CEO pay percentile vs peers
CEO-to-median pay ratio
93.91%
Say-on-pay support, latest vote
Companies that benchmark against WGS
5 companies name WGS as a compensation peer

Each company listed discloses WGS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named WGS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Katherine Stueland$715,869$0$11,738,600$0$1,075,500$0$17,250$13,547,219
Chief Executive Officer
Kevin Feeley500,60003,756,9260414,150017,2504,688,926
Chief Financial Officer
Bryan Dechairo436,15475,0002,699,9710371,250003,582,375
Chief Operating Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Katherine Stueland$13,547,219$4,421,800+9,125,419
Kevin Feeley4,688,9261,349,600+3,339,326
Bryan Dechairo3,582,375

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Keith MeisterDirector2026-05-07A73,104$41$3,008,230Common, indirectForm 4 ↗
Casdin Capital, LLCDirector2026-05-07A50,000Derivative, Class A CommonForm 4 ↗
Keith MeisterDirector2026-05-07A5324021,466Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A246,734399,600,420Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A94,356393,716,683Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A123,393384,639,577Common, indirectForm 4 ↗
Casdin Capital, LLCDirector2026-05-07A500,000Derivative, Class A CommonForm 4 ↗
Casdin Capital, LLCDirector2026-05-07A300,000Derivative, Class A CommonForm 4 ↗
Keith MeisterDirector2026-05-07A56,630402,291,250Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A14,78636537,175Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A128,181354,545,298Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A79,144413,218,786Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A15,74538598,310Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A116,412384,477,206Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A3,39639131,425Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A252,7344010,020,903Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-13A51,893402,071,569Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-13A18,86540751,393Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-13A94,074393,651,953Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-13A70,926392,798,031Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-13A88,107393,443,222Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-13A27,408381,049,178Common, indirectForm 4 ↗
Casdin Capital, LLCDirector2026-05-18A140,000446,132,854CommonForm 4 ↗
Casdin Capital, LLCDirector2026-05-18A175,000437,446,548CommonForm 4 ↗
Casdin Capital, LLCDirector2026-05-18A185,000437,880,334CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-01A71700CommonForm 4 ↗
Dividend-equivalent accruals2026-06-017171 insider, 1 accrual row
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-01D3695219,092CommonForm 4 ↗
Casdin Capital, LLCDirector2026-06-04A150,000568,466,735CommonForm 4 ↗
Casdin Capital, LLCDirector2026-06-04A50,000532,642,830CommonForm 4 ↗
Katherine StuelandDirector2026-06-09A6,54600CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-09D2,46200Derivative, Class A CommonForm 4 ↗
Katherine StuelandDirector2026-06-09D6,54600Derivative, Class A CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-09A2,46200CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-09D1,2665468,073CommonForm 4 ↗
Katherine StuelandDirector2026-06-09D3,63954195,669CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-16A7,19700CommonForm 4 ↗
Katherine StuelandDirector2026-06-16A18,75000CommonForm 4 ↗
Katherine StuelandDirector2026-06-16D5,93261360,838CommonForm 4 ↗
Katherine StuelandDirector2026-06-16D18,75000Derivative, Class A CommonForm 4 ↗
Katherine StuelandDirector2026-06-16D2,14060127,874CommonForm 4 ↗
Katherine StuelandDirector2026-06-16D2,42962149,392CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-16D2,10661128,106CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-16D7,19700Derivative, Class A CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-16D8636253,078CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-16D7606045,413CommonForm 4 ↗
Richard C. Pfenniger, JrDirector2026-06-18A3,57600CommonForm 4 ↗
Keith MeisterDirector2026-06-18D3,57600Derivative, Class A CommonForm 4 ↗
Jason RyanDirector2026-06-18D3,57600Derivative, Class A CommonForm 4 ↗
Emily LeproustDirector2026-06-18A3,57600CommonForm 4 ↗
Emily LeproustDirector2026-06-18D3,57600Derivative, Class A CommonForm 4 ↗
Thomas FuchsDirector2026-06-18A4,24800Derivative, Class A CommonForm 4 ↗
Eli D. CasdinDirector2026-06-18A3,57600CommonForm 4 ↗
Eli D. CasdinDirector2026-06-18A4,24800Derivative, Class A CommonForm 4 ↗
Richard C. Pfenniger, JrDirector2026-06-18A4,24800Derivative, Class A CommonForm 4 ↗
Eli D. CasdinDirector2026-06-18D3,57600Derivative, Class A CommonForm 4 ↗
Keith MeisterDirector2026-06-18A4,24800Derivative, Class A CommonForm 4 ↗
Joshua RuchDirector2026-06-18D3,57600Derivative, Class A CommonForm 4 ↗
Jason RyanDirector2026-06-18A3,57600CommonForm 4 ↗
Joshua RuchDirector2026-06-18A3,57600CommonForm 4 ↗
Keith MeisterDirector2026-06-18A3,57600CommonForm 4 ↗
Joshua RuchDirector2026-06-18A4,24800Derivative, Class A CommonForm 4 ↗
Emily LeproustDirector2026-06-18A4,24800Derivative, Class A CommonForm 4 ↗
Richard C. Pfenniger, JrDirector2026-06-18D3,57600Derivative, Class A CommonForm 4 ↗
Mark A. GardnerPresident2026-06-29A35,44100Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 65 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Keith MeisterDirector2026-05-07A73,104$41$3,008,230Common, indirectForm 4 ↗
Casdin Capital, LLCDirector2026-05-07A50,000Derivative, Class A CommonForm 4 ↗
Keith MeisterDirector2026-05-07A5324021,466Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A246,734399,600,420Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A94,356393,716,683Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A123,393384,639,577Common, indirectForm 4 ↗
Casdin Capital, LLCDirector2026-05-07A500,000Derivative, Class A CommonForm 4 ↗
Casdin Capital, LLCDirector2026-05-07A300,000Derivative, Class A CommonForm 4 ↗
Keith MeisterDirector2026-05-07A56,630402,291,250Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A14,78636537,175Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A128,181354,545,298Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A79,144413,218,786Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A15,74538598,310Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A116,412384,477,206Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A3,39639131,425Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-07A252,7344010,020,903Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-13A51,893402,071,569Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-13A18,86540751,393Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-13A94,074393,651,953Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-13A70,926392,798,031Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-13A88,107393,443,222Common, indirectForm 4 ↗
Keith MeisterDirector2026-05-13A27,408381,049,178Common, indirectForm 4 ↗
Casdin Capital, LLCDirector2026-05-18A140,000446,132,854CommonForm 4 ↗
Casdin Capital, LLCDirector2026-05-18A175,000437,446,548CommonForm 4 ↗
Casdin Capital, LLCDirector2026-05-18A185,000437,880,334CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-01A71700CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-01D71700Derivative, Class A CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-01D3695219,092CommonForm 4 ↗
Casdin Capital, LLCDirector2026-06-04A150,000568,466,735CommonForm 4 ↗
Casdin Capital, LLCDirector2026-06-04A50,000532,642,830CommonForm 4 ↗
Katherine StuelandDirector2026-06-09A6,54600CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-09D2,46200Derivative, Class A CommonForm 4 ↗
Katherine StuelandDirector2026-06-09D6,54600Derivative, Class A CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-09A2,46200CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-09D1,2665468,073CommonForm 4 ↗
Katherine StuelandDirector2026-06-09D3,63954195,669CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-16A7,19700CommonForm 4 ↗
Katherine StuelandDirector2026-06-16A18,75000CommonForm 4 ↗
Katherine StuelandDirector2026-06-16D5,93261360,838CommonForm 4 ↗
Katherine StuelandDirector2026-06-16D18,75000Derivative, Class A CommonForm 4 ↗
Katherine StuelandDirector2026-06-16D2,14060127,874CommonForm 4 ↗
Katherine StuelandDirector2026-06-16D2,42962149,392CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-16D2,10661128,106CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-16D7,19700Derivative, Class A CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-16D8636253,078CommonForm 4 ↗
Kevin FeeleyCHIEF FINANCIAL OFFICER2026-06-16D7606045,413CommonForm 4 ↗
Richard C. Pfenniger, JrDirector2026-06-18A3,57600CommonForm 4 ↗
Keith MeisterDirector2026-06-18D3,57600Derivative, Class A CommonForm 4 ↗
Jason RyanDirector2026-06-18D3,57600Derivative, Class A CommonForm 4 ↗
Emily LeproustDirector2026-06-18A3,57600CommonForm 4 ↗
Emily LeproustDirector2026-06-18D3,57600Derivative, Class A CommonForm 4 ↗
Thomas FuchsDirector2026-06-18A4,24800Derivative, Class A CommonForm 4 ↗
Eli D. CasdinDirector2026-06-18A3,57600CommonForm 4 ↗
Eli D. CasdinDirector2026-06-18A4,24800Derivative, Class A CommonForm 4 ↗
Richard C. Pfenniger, JrDirector2026-06-18A4,24800Derivative, Class A CommonForm 4 ↗
Eli D. CasdinDirector2026-06-18D3,57600Derivative, Class A CommonForm 4 ↗
Keith MeisterDirector2026-06-18A4,24800Derivative, Class A CommonForm 4 ↗
Joshua RuchDirector2026-06-18D3,57600Derivative, Class A CommonForm 4 ↗
Jason RyanDirector2026-06-18A3,57600CommonForm 4 ↗
Joshua RuchDirector2026-06-18A3,57600CommonForm 4 ↗
Keith MeisterDirector2026-06-18A3,57600CommonForm 4 ↗
Joshua RuchDirector2026-06-18A4,24800Derivative, Class A CommonForm 4 ↗
Emily LeproustDirector2026-06-18A4,24800Derivative, Class A CommonForm 4 ↗
Richard C. Pfenniger, JrDirector2026-06-18D3,57600Derivative, Class A CommonForm 4 ↗
Mark A. GardnerPresident2026-06-29A35,44100Derivative, Class A CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Bryan DechairoRSU2025-01-1437,497$2,699,971
Katherine StuelandRSU2025-03-1547,6844,695,443
Kevin FeeleyPSU2025-03-156,1057,63115,2612,254,175
Kevin FeeleyRSU2025-03-1515,2611,502,751
Katherine StuelandPSU2025-03-1519,07423,84247,6847,043,165
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Bryan Dechairo$2,699,971$0$00.0%
Katherine Stueland4,695,4437,043,165060.0%
Kevin Feeley1,502,7512,254,175060.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Katherine StuelandPSU47,684$6,201,781
Katherine StuelandRSU240,00031,214,400
Kevin FeeleyRSU15,2611,984,846
Katherine StuelandRSU93,75012,193,125
Kevin FeeleyRSU48,7506,340,425
Bryan DechairoRSU37,4972,699,971
Katherine StuelandRSU7,7481,007,705
Kevin FeeleyRSU2,152279,889
Kevin FeeleyPSU7,630992,358
Kevin FeeleyRSU1,508196,131
Kevin FeeleyOption3,73732.67
Kevin FeeleyRSU9,8491,280,961
Katherine StuelandOption13,45272.6
Kevin FeeleyOption2,61672.6
Katherine StuelandRSU47,6846,201,781
Kevin FeeleyRSU35,9844,680,079
Katherine StuelandRSU26,1863,405,751
05

Incentive-plan design — the Compensation Discussion & Analysis

GeneDx's executive compensation program is designed to attract, motivate, and retain highly qualified leaders who can execute the Company's growth strategy, advance innovation in genetic testing and diagnostics, and deliver sustainable long-term stockholder value.

CEO STI target (% of salary)100%
CEO LTI target (% of salary)
Independent consultantPearl Meyer
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-1822,705,9461,471,59341,82193.91%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1893.91%a

a. Approved under the standard stated in the filing — “At the Annual Meeting, abstentions will have no effect on Proposal No.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Thomas FuchsIndependent · Partial-year service · Newly elected$14,402$439,789$0$0$0$454,191
Jason RyanNot independent · Board Chair · Not standing for re-election94,278230,40200-1324,679
Emily LeproustIndependent · Audit · Compensation · Nominating/Governance (Chair) · NOMINATING AND CORPORATE GOVERNANCE COMMITTEE (Chair)74,639230,402000305,041
Keith MeisterIndependent · Audit (Chair) · AUDIT COMMITTEE (Chair)67,139230,402000297,541
Joshua RuchIndependent · Compensation (Chair) · Nominating/Governance · COMPENSATION COMMITTEE (Chair)67,139230,402000297,541
Eli D. CasdinIndependent · Compensation · Nominating/Governance59,639230,402000290,041
Richard C. Pfenniger, JrIndependent · Audit57,139230,402000287,541
Katherine StuelandEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$338,480
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)10,000 / 7,500 / 5,000
Stock ownership guideline300% of annual cash director retainer
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$434,375
Equity awards (grant-date value)$1,822,201
All other compensation$-1
Total cost of the board$2,256,575

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies GeneDx Holdings names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including GeneDx Holdings.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Natera2025Steven Chapman$853,710$12,979,558$0$1,114,151$14,957,319
2GeneDx Holdings2025Katherine Stueland715,86911,738,60001,075,50013,547,219
3Mirum Pharmaceuticals2025Christopher Peetz755,0003,683,9044,931,3201,057,00010,441,224
4NeoGenomics2025Tony Zook601,5393,999,9973,998,235513,4009,127,092
5Axogen2025Michael Dale775,8657,342,8950906,1339,047,454
6Standard BioTools2025Michael Egholm680,2565,337,8831,671,3631,120,0008,823,502
7Veracyte2025Marc Stapley700,0005,890,8770826,0007,421,877
8CareDx2025John Hanna693,2695,622,6380852,5157,179,699
9Castle Biosciences2025Derek Maetzold751,3504,977,20801,036,8636,786,771
1010x Genomics2025Serge Saxonov674,2505,020,2690634,7256,329,244
11Pacific Biosciences of California2025Christian Henry748,2501,151,0131,696,278714,3054,309,846
12Cerus2025William Greenman793,7502,242,5850756,0003,794,657

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
GeneDx Holdings150%PSU 50 · RSU 50NoPearl Meyer
10x Genomics93%PSU 60 · RSU 40Yes — 3-year Relative TSRAlpine Rewards LLC
Axogen116.79%PSU 50 · RSU 50NoAon
CareDx122%RSU 70 · PSU 30NoAlpine Rewards
Castle Biosciences138%RSU 50 · PSU 50NoAON (AON's Human Capital Solutions Practice, a division of AON plc)
Cerus126%RSU 75 · PSU 25NoAlpine
Mirum Pharmaceuticals200%not disclosedNoAlpine Rewards
Natera131.1%PSU 50 · RSU 50NoAon
NeoGenomics60%RSU 50 · Options 50not disclosedWTW
Pacific Biosciences of California95%not disclosednot disclosedAon Human Capital Solutions
Standard BioTools160%not disclosednot disclosedPearl Meyer
Veracyte118%PSU 50 · RSU 50NoAon

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Katherine StuelandDEF 14A2026-04-300001818331-26-000030Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 13,547,219. Filing ↗machine: span 565318–565328
2Section 01, Kevin FeeleyDEF 14A2026-04-300001818331-26-000030Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 4,688,926. Filing ↗machine: span 575385–575394
3Section 01, Bryan DechairoDEF 14A2026-04-300001818331-26-000030Section “2025 SUMMARY COMPENSATION TABLE”. As printed: 3,582,375. Filing ↗machine: r8 · c42 · span 584613–584622
4Section 03, Bryan Dechairo RSUDEF 14A2026-04-300001818331-26-000030Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t33 · r18 · c23 · span 645622–645631
5Section 03, Katherine Stueland RSUDEF 14A2026-04-300001818331-26-000030Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t33 · r6 · c23 · span 614595–614604
6Section 03, Kevin Feeley PSUDEF 14A2026-04-300001818331-26-000030Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t33 · r14 · c23 · span 634583–634592
7Section 03, Kevin Feeley RSUDEF 14A2026-04-300001818331-26-000030Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t33 · r12 · c23 · span 630007–630016
8Section 03, Katherine Stueland PSUDEF 14A2026-04-300001818331-26-000030Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t33 · r8 · c23 · span 619836–619845
9Section 07, pay ratioDEF 14A2026-04-300001818331-26-000030Section “CEO Pay Ratio”. As printed: —. Filing ↗
10Section 08, Thomas FuchsDEF 14A2026-04-300001818331-26-000030Section “Director Compensation”. As printed: 454,191. Filing ↗machine: t11 · r8 · c11 · span 226320–226327
11Section 08, Jason RyanDEF 14A2026-04-300001818331-26-000030Section “Director Compensation”. As printed: 324,679. Filing ↗machine: t11 · r7 · c11 · span 223672–223679
12Section 08, Emily LeproustDEF 14A2026-04-300001818331-26-000030Section “Director Compensation”. As printed: 305,041. Filing ↗machine: t11 · r4 · c11 · span 215736–215743
13Section 08, Keith MeisterDEF 14A2026-04-300001818331-26-000030Section “Director Compensation”. As printed: 297,541. Filing ↗machine: t11 · r5 · c11 · span 218378–218385
14Section 08, Joshua RuchDEF 14A2026-04-300001818331-26-000030Section “Director Compensation”. As printed: 297,541. Filing ↗machine: t11 · r2 · c11 · span 210413–210420
15Section 08, Eli D. CasdinDEF 14A2026-04-300001818331-26-000030Section “Director Compensation”. As printed: 290,041. Filing ↗machine: t11 · r3 · c11 · span 213086–213093
16Section 08, Richard C. Pfenniger, JrDEF 14A2026-04-300001818331-26-000030Section “Director Compensation”. As printed: 287,541. Filing ↗machine: t11 · r6 · c11 · span 221033–221040
17Section 08, Katherine StuelandDEF 14A2026-04-300001818331-26-000030Section “Director Compensation”. As printed: 0. Filing ↗
18Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Casdin Capital, LLC 2026-05-07Form 42026-05-110000919574-26-002845Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Casdin Capital, LLC 2026-05-07Form 42026-05-110000919574-26-002845Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Casdin Capital, LLC 2026-05-07Form 42026-05-110000919574-26-002845Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Keith Meister 2026-05-07Form 42026-05-110001011438-26-000276Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Keith Meister 2026-05-13Form 42026-05-150001011438-26-000351Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Keith Meister 2026-05-13Form 42026-05-150001011438-26-000351Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Keith Meister 2026-05-13Form 42026-05-150001011438-26-000351Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Keith Meister 2026-05-13Form 42026-05-150001011438-26-000351Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Keith Meister 2026-05-13Form 42026-05-150001011438-26-000351Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Keith Meister 2026-05-13Form 42026-05-150001011438-26-000351Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Casdin Capital, LLC 2026-05-18Form 42026-05-200000919574-26-003627Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Casdin Capital, LLC 2026-05-18Form 42026-05-200000919574-26-003627Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Casdin Capital, LLC 2026-05-18Form 42026-05-200000919574-26-003627Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Kevin Feeley 2026-06-01Form 42026-06-030001944119-26-000027Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Kevin Feeley 2026-06-01Form 42026-06-030001944119-26-000027Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Kevin Feeley 2026-06-01Form 42026-06-030001944119-26-000027Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Casdin Capital, LLC 2026-06-04Form 42026-06-080000919574-26-003907Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Casdin Capital, LLC 2026-06-04Form 42026-06-080000919574-26-003907Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Katherine Stueland 2026-06-09Form 42026-06-110001689575-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Kevin Feeley 2026-06-09Form 42026-06-110001944119-26-000029Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Katherine Stueland 2026-06-09Form 42026-06-110001689575-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Kevin Feeley 2026-06-09Form 42026-06-110001944119-26-000029Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Kevin Feeley 2026-06-09Form 42026-06-110001944119-26-000029Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Katherine Stueland 2026-06-09Form 42026-06-110001689575-26-000026Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Kevin Feeley 2026-06-16Form 42026-06-180001944119-26-000031Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Katherine Stueland 2026-06-16Form 42026-06-180001689575-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Katherine Stueland 2026-06-16Form 42026-06-180001689575-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Katherine Stueland 2026-06-16Form 42026-06-180001689575-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Katherine Stueland 2026-06-16Form 42026-06-180001689575-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Katherine Stueland 2026-06-16Form 42026-06-180001689575-26-000028Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Kevin Feeley 2026-06-16Form 42026-06-180001944119-26-000031Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Kevin Feeley 2026-06-16Form 42026-06-180001944119-26-000031Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Kevin Feeley 2026-06-16Form 42026-06-180001944119-26-000031Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Kevin Feeley 2026-06-16Form 42026-06-180001944119-26-000031Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Richard C. Pfenniger, Jr 2026-06-18Form 42026-06-230001200796-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Keith Meister 2026-06-18Form 42026-06-230001307631-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Jason Ryan 2026-06-18Form 42026-06-230001585017-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Emily Leproust 2026-06-18Form 42026-06-230001753655-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Emily Leproust 2026-06-18Form 42026-06-230001753655-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Thomas Fuchs 2026-06-18Form 42026-06-230002083937-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Eli D. Casdin 2026-06-18Form 42026-06-230001534264-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Eli D. Casdin 2026-06-18Form 42026-06-230001534264-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Richard C. Pfenniger, Jr 2026-06-18Form 42026-06-230001200796-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Eli D. Casdin 2026-06-18Form 42026-06-230001534264-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Keith Meister 2026-06-18Form 42026-06-230001307631-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Joshua Ruch 2026-06-18Form 42026-06-230000943431-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Jason Ryan 2026-06-18Form 42026-06-230001585017-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Joshua Ruch 2026-06-18Form 42026-06-230000943431-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Keith Meister 2026-06-18Form 42026-06-230001307631-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Joshua Ruch 2026-06-18Form 42026-06-230000943431-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Emily Leproust 2026-06-18Form 42026-06-230001753655-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Richard C. Pfenniger, Jr 2026-06-18Form 42026-06-230001200796-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Mark A. Gardner 2026-06-29Form 42026-07-010001955242-26-000011Insider equity transaction reported since the proxy statement. Filing ↗
83Section 06, 2026 voteForm 8-K2026-06-230001628280-26-044806Item 5.07 · say-on-pay result. As reported: 93.91% (votes for as printed: 22,705,946). Filing ↗
84Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
85Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
86Section 09b board cost (computed)ComputedcomputedCash 434,375 + equity 1,822,201 + all other -1 = 2,256,575, summed across the director compensation table rows.machine: formula: Σ = 2,256,575
87Natera, Section 10b CEO totalDEF 14A2026-04-230001104659-26-047770CEO total compensation as printed in Natera's own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878
88GeneDx Holdings (subject), Section 10b CEO totalDEF 14A2026-04-300001818331-26-000030CEO total compensation as printed in GeneDx Holdings's own proxy. As printed: 13,547,219. Filing ↗machine: span 565318–565328
89Mirum Pharmaceuticals, Section 10b CEO totalDEF 14A2026-04-230001759425-26-000027CEO total compensation as printed in Mirum Pharmaceuticals's own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210
90NeoGenomics, Section 10b CEO totalDEF 14A2026-04-060001077183-26-000014CEO total compensation as printed in NeoGenomics's own proxy. As printed: 9,127,092. Filing ↗machine: r2 · c45 · span 869460–869469
91Axogen, Section 10b CEO totalDEF 14A2026-04-290000805928-26-000057CEO total compensation as printed in Axogen's own proxy. As printed: 9,047,454. Filing ↗machine: r2 · c45 · span 557309–557318
92Standard BioTools, Section 10b CEO totalDEF 14A2026-04-270001140361-26-017100CEO total compensation as printed in Standard BioTools's own proxy. As printed: 8,823,502. Filing ↗machine: r2 · c22 · span 553256–553266
93Veracyte, Section 10b CEO totalDEF 14A2026-04-220001384101-26-000021CEO total compensation as printed in Veracyte's own proxy. As printed: 7,421,877. Filing ↗machine: r4 · c27 · span 855413–855422
94CareDx, Section 10b CEO totalDEF 14A2026-04-270001217234-26-000028CEO total compensation as printed in CareDx's own proxy. As printed: 7,179,699. Filing ↗machine: t113 · r3 · c9 · span 1893652–1893661
95Castle Biosciences, Section 10b CEO totalDEF 14A2026-04-080001628280-26-024166CEO total compensation as printed in Castle Biosciences's own proxy. As printed: 6,786,771. Filing ↗machine: r3 · c24 · span 933087–933096
9610x Genomics, Section 10b CEO totalDEF 14A2026-04-240001628280-26-027201CEO total compensation as printed in 10x Genomics's own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292
97Pacific Biosciences of California, Section 10b CEO totalDEF 14A2026-04-230001299130-26-000064CEO total compensation as printed in Pacific Biosciences of California's own proxy. As printed: 4,309,846. Filing ↗machine: r2 · c48 · span 876974–876983
98Cerus, Section 10b CEO totalDEF 14A2026-04-220001020214-26-000011CEO total compensation as printed in Cerus's own proxy. As printed: 3,794,657. Filing ↗machine: span 1301658–1301667
99Section 10a, Castle Biosciences reciprocityDEF 14A0001628280-26-024166Castle Biosciences names GeneDx Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗
100Section 10a, Mirum Pharmaceuticals reciprocityDEF 14A0001759425-26-000027Mirum Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include GeneDx Holdings. Filing ↗
101Section 10a, 10x Genomics reciprocityDEF 14A0001628280-26-02720110x Genomics's most recent proxy was read; its disclosed peer group does not include GeneDx Holdings. Filing ↗
102Section 10a, NeoGenomics reciprocityDEF 14A0001077183-26-000014NeoGenomics's most recent proxy was read; its disclosed peer group does not include GeneDx Holdings. Filing ↗
103Section 10a, Standard BioTools reciprocityDEF 14A0001140361-26-017100Standard BioTools's most recent proxy was read; its disclosed peer group does not include GeneDx Holdings. Filing ↗
104Section 10a, Veracyte reciprocityDEF 14A0001384101-26-000021Veracyte's most recent proxy was read; its disclosed peer group does not include GeneDx Holdings. Filing ↗
105Section 10a, Pacific Biosciences of California reciprocityDEF 14A0001299130-26-000064Pacific Biosciences of California's most recent proxy was read; its disclosed peer group does not include GeneDx Holdings. Filing ↗
106Section 10a, CareDx reciprocityDEF 14A0001217234-26-000028CareDx's most recent proxy was read; its disclosed peer group does not include GeneDx Holdings. Filing ↗
107Section 10a, Axogen reciprocityDEF 14A0000805928-26-000057Axogen's most recent proxy was read; its disclosed peer group does not include GeneDx Holdings. Filing ↗
108Section 10a, Cerus reciprocityDEF 14A0001020214-26-000011Cerus's most recent proxy was read; its disclosed peer group does not include GeneDx Holdings. Filing ↗
109Section 10a, Natera reciprocityDEF 14A0001104659-26-047770Natera's most recent proxy was read; its disclosed peer group does not include GeneDx Holdings. Filing ↗